サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1117744

世界の動脈硬化治療薬市場：考察と予測 (2028年まで)

Global Atherosclerosis Drugs Market Insights, Forecast to 2028
出版日: | 発行: QYResearch | ページ情報: 英文 104 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
世界の動脈硬化治療薬市場：考察と予測 (2028年まで)
出版日: 2022年08月23日
発行: QYResearch
ページ情報: 英文 104 Pages
納期: 2～3営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートは、動脈硬化治療薬 (Atherosclerosis Drugs) 市場について調査しており、市場規模や動向・需要の予測、成長要因および課題の分析、タイプ・用途・企業・地域別の内訳、競合情勢、主要企業のプロファイルなどの情報を提供しています。

目次

第1章 レポート概要

  • 調査範囲
  • 市場分析：タイプ別
    • 世界の動脈硬化治療薬の市場規模成長率：タイプ別, 2017 VS 2021 VS 2028
    • Corticosteroids
    • PDE4 Inhibitors
    • Biologics
    • Skin Barrier Emollients
    • CNI Immunosuppressants
    • Others
  • 市場：アプリケーション別
    • 世界の動脈硬化治療薬の市場規模成長率：アプリケーション別, 2017 VS 2021 VS 2028
    • Hospital
    • Clinic
    • Retail Pharmacies
    • Other
  • 調査目的
  • 対象期間

第2章 世界の市場成長トレンド

  • 世界の動脈硬化治療薬の市場展望 (2017-2028)
  • 動脈硬化治療薬の市場成長トレンド：地域別
    • 動脈硬化治療薬 市場規模：地域別: 2017 VS 2021 VS 2028
    • 動脈硬化治療薬の市場規模実績：地域別 (2017-2022)
    • 動脈硬化治療薬の市場規模予測：地域別 (2023-2028)
  • 動脈硬化治療薬 市場動向
    • 動脈硬化治療薬 業界動向
    • 動脈硬化治療薬 市場の促進要因
    • 動脈硬化治療薬 市場の課題
    • 動脈硬化治療薬 市場の抑制要因

第3章 競合情勢：主要企業別

  • 世界の動脈硬化治療薬の上位企業：収益別
    • 世界の動脈硬化治療薬の上位企業：収益別 (2017-2022)
    • 世界の動脈硬化治療薬の収益シェア：企業別 (2017-2022)
  • 世界の動脈硬化治療薬の市場シェア：企業タイプ別 (Tier 1, Tier 2, and Tier 3)
  • 企業ランキング：動脈硬化治療薬の収益
  • 世界の動脈硬化治療薬 市場集中度
    • 世界の動脈硬化治療薬 市場集中度 (CR5 and HHI)
    • 世界の上位10・上位5企業： 動脈硬化治療薬の収益 2021
  • 動脈硬化治療薬の主要企業の本社および事業エリア
  • 主要企業 動脈硬化治療薬の製品ソリューションおよびサービス
  • 市場参入時期： 動脈硬化治療薬 市場
  • M&A, 拡張計画

第4章 動脈硬化治療薬 内訳データ：タイプ別

  • 世界の動脈硬化治療薬の市場規模実績：タイプ別 (2017-2022)
  • 世界の動脈硬化治療薬の市場規模予測：タイプ別 (2023-2028)

第5章 動脈硬化治療薬 内訳データ：アプリケーション別

  • 世界の動脈硬化治療薬の市場規模実績：アプリケーション別 (2017-2022)
  • 世界の動脈硬化治療薬の市場規模予測：アプリケーション別 (2023-2028)

第6章 北米

  • 北米の動脈硬化治療薬 市場規模 (2017-2028)
  • 北米の動脈硬化治療薬 市場規模：タイプ別
    • 北米の動脈硬化治療薬 市場規模：タイプ別 (2017-2022)
    • 北米の動脈硬化治療薬 市場規模：タイプ別 (2023-2028)
    • 北米の動脈硬化治療薬の市場シェア：タイプ別 (2017-2028)
  • 北米の動脈硬化治療薬 市場規模：アプリケーション別
    • 北米の動脈硬化治療薬 市場規模：アプリケーション別 (2017-2022)
    • 北米の動脈硬化治療薬 市場規模：アプリケーション別 (2023-2028)
    • 北米の動脈硬化治療薬の市場シェア：アプリケーション別 (2017-2028)
  • 北米の動脈硬化治療薬 市場規模：国別
    • 北米の動脈硬化治療薬 市場規模：国別 (2017-2022)
    • 北米の動脈硬化治療薬 市場規模：国別 (2023-2028)
    • 米国
    • カナダ

第7章 欧州

  • 欧州の動脈硬化治療薬 市場規模 (2017-2028)
  • 欧州の動脈硬化治療薬 市場規模：タイプ別
    • 欧州の動脈硬化治療薬 市場規模：タイプ別 (2017-2022)
    • 欧州の動脈硬化治療薬 市場規模：タイプ別 (2023-2028)
    • 欧州の動脈硬化治療薬の市場シェア：タイプ別 (2017-2028)
  • 欧州の動脈硬化治療薬 市場規模：アプリケーション別
    • 欧州の動脈硬化治療薬 市場規模：アプリケーション別 (2017-2022)
    • 欧州の動脈硬化治療薬 市場規模：アプリケーション別 (2023-2028)
    • 欧州の動脈硬化治療薬の市場シェア：アプリケーション別 (2017-2028)
  • 欧州の動脈硬化治療薬 市場規模：国別
    • 欧州の動脈硬化治療薬 市場規模：国別 (2017-2022)
    • 欧州の動脈硬化治療薬 市場規模：国別 (2023-2028)
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • ロシア
    • 北欧

第8章 アジア太平洋地域

  • アジア太平洋地域 動脈硬化治療薬 市場規模 (2017-2028)
  • アジア太平洋地域 動脈硬化治療薬 市場規模：タイプ別
    • アジア太平洋地域 動脈硬化治療薬 市場規模：タイプ別 (2017-2022)
    • アジア太平洋地域 動脈硬化治療薬 市場規模：タイプ別 (2023-2028)
    • アジア太平洋地域 動脈硬化治療薬の市場シェア：タイプ別 (2017-2028)
  • アジア太平洋地域 動脈硬化治療薬 市場規模：アプリケーション別
    • アジア太平洋地域 動脈硬化治療薬 市場規模：アプリケーション別 (2017-2022)
    • アジア太平洋地域 動脈硬化治療薬 市場規模：アプリケーション別 (2023-2028)
    • アジア太平洋地域 動脈硬化治療薬の市場シェア：アプリケーション別 (2017-2028)
  • アジア太平洋地域 動脈硬化治療薬 市場規模：地域別
    • アジア太平洋地域 動脈硬化治療薬 市場規模：地域別 (2017-2022)
    • アジア太平洋地域 動脈硬化治療薬 市場規模：地域別 (2023-2028)
    • 中国
    • 日本
    • 韓国
    • 東南アジア
    • インド
    • オーストラリア

第9章 ラテンアメリカ

  • ラテンアメリカの動脈硬化治療薬 市場規模 (2017-2028)
  • ラテンアメリカの動脈硬化治療薬 市場規模：タイプ別
    • ラテンアメリカの動脈硬化治療薬 市場規模：タイプ別 (2017-2022)
    • ラテンアメリカの動脈硬化治療薬 市場規模：タイプ別 (2023-2028)
    • ラテンアメリカの動脈硬化治療薬の市場シェア：タイプ別 (2017-2028)
  • ラテンアメリカの動脈硬化治療薬 市場規模：アプリケーション別
    • ラテンアメリカの動脈硬化治療薬 市場規模：アプリケーション別 (2017-2022)
    • ラテンアメリカの動脈硬化治療薬 市場規模：アプリケーション別 (2023-2028)
    • ラテンアメリカの動脈硬化治療薬の市場シェア：アプリケーション別 (2017-2028)
  • ラテンアメリカの動脈硬化治療薬 市場規模：国別
    • ラテンアメリカの動脈硬化治療薬 市場規模：国別 (2017-2022)
    • ラテンアメリカの動脈硬化治療薬 市場規模：国別 (2023-2028)
    • メキシコ
    • ブラジル

第10章 中東・アフリカ

  • 中東・アフリカの動脈硬化治療薬 市場規模 (2017-2028)
  • 中東・アフリカの動脈硬化治療薬 市場規模：タイプ別
    • 中東・アフリカの動脈硬化治療薬 市場規模：タイプ別 (2017-2022)
    • 中東・アフリカの動脈硬化治療薬 市場規模：タイプ別 (2023-2028)
    • 中東・アフリカの動脈硬化治療薬の市場シェア：タイプ別 (2017-2028)
  • 中東・アフリカの動脈硬化治療薬 市場規模：アプリケーション別
    • 中東・アフリカの動脈硬化治療薬 市場規模：アプリケーション別 (2017-2022)
    • 中東・アフリカの動脈硬化治療薬 市場規模：アプリケーション別 (2023-2028)
    • 中東・アフリカの動脈硬化治療薬の市場シェア：アプリケーション別 (2017-2028)
  • 中東・アフリカの動脈硬化治療薬 市場規模：国別
    • 中東・アフリカの動脈硬化治療薬 市場規模：国別 (2017-2022)
    • 中東・アフリカの動脈硬化治療薬 市場規模：国別 (2023-2028)
    • トルコ
    • サウジアラビア
    • UAE

第11章 主要企業のプロファイル

  • GlaxoSmithKline
  • Sanofi
  • F. Hoffmann-L a Roche
  • Bayer
  • Novartis
  • Merck
  • Janssen Pharmaceutical
  • Amgen
  • Pfizer

第12章 アナリストによる分析/結論

第13章 付録

図表
  • Table 1. Global Atherosclerosis Drugs Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
  • Table 2. Key Players of Corticosteroids
  • Table 3. Key Players of PDE4 Inhibitors
  • Table 4. Key Players of Biologics
  • Table 5. Key Players of Skin Barrier Emollients
  • Table 6. Key Players of CNI Immunosuppressants
  • Table 7. Key Players of Others
  • Table 8. Global Atherosclerosis Drugs Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
  • Table 9. Global Atherosclerosis Drugs Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
  • Table 10. Global Atherosclerosis Drugs Market Size by Region (2017-2022) & (US$ Million)
  • Table 11. Global Atherosclerosis Drugs Market Share by Region (2017-2022)
  • Table 12. Global Atherosclerosis Drugs Forecasted Market Size by Region (2023-2028) & (US$ Million)
  • Table 13. Global Atherosclerosis Drugs Market Share by Region (2023-2028)
  • Table 14. Atherosclerosis Drugs Market Trends
  • Table 15. Atherosclerosis Drugs Market Drivers
  • Table 16. Atherosclerosis Drugs Market Challenges
  • Table 17. Atherosclerosis Drugs Market Restraints
  • Table 18. Global Atherosclerosis Drugs Revenue by Players (2017-2022) & (US$ Million)
  • Table 19. Global Atherosclerosis Drugs Revenue Share by Players (2017-2022)
  • Table 20. Global Top Atherosclerosis Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Atherosclerosis Drugs as of 2021)
  • Table 21. Ranking of Global Top Atherosclerosis Drugs Companies by Revenue (US$ Million) in 2021
  • Table 22. Global 5 Largest Players Market Share by Atherosclerosis Drugs Revenue (CR5 and HHI) & (2017-2022)
  • Table 23. Key Players Headquarters and Area Served
  • Table 24. Key Players Atherosclerosis Drugs Product Solution and Service
  • Table 25. Date of Enter into Atherosclerosis Drugs Market
  • Table 26. Mergers & Acquisitions, Expansion Plans
  • Table 27. Global Atherosclerosis Drugs Market Size by Type (2017-2022) & (US$ Million)
  • Table 28. Global Atherosclerosis Drugs Revenue Market Share by Type (2017-2022)
  • Table 29. Global Atherosclerosis Drugs Forecasted Market Size by Type (2023-2028) & (US$ Million)
  • Table 30. Global Atherosclerosis Drugs Revenue Market Share by Type (2023-2028)
  • Table 31. Global Atherosclerosis Drugs Market Size by Application (2017-2022) & (US$ Million)
  • Table 32. Global Atherosclerosis Drugs Revenue Share by Application (2017-2022)
  • Table 33. Global Atherosclerosis Drugs Forecasted Market Size by Application (2023-2028) & (US$ Million)
  • Table 34. Global Atherosclerosis Drugs Revenue Share by Application (2023-2028)
  • Table 35. North America Atherosclerosis Drugs Market Size by Type (2017-2022) & (US$ Million)
  • Table 36. North America Atherosclerosis Drugs Market Size by Type (2023-2028) & (US$ Million)
  • Table 37. North America Atherosclerosis Drugs Market Size by Application (2017-2022) & (US$ Million)
  • Table 38. North America Atherosclerosis Drugs Market Size by Application (2023-2028) & (US$ Million)
  • Table 39. North America Atherosclerosis Drugs Market Size by Country (2017-2022) & (US$ Million)
  • Table 40. North America Atherosclerosis Drugs Market Size by Country (2023-2028) & (US$ Million)
  • Table 41. Europe Atherosclerosis Drugs Market Size by Type (2017-2022) & (US$ Million)
  • Table 42. Europe Atherosclerosis Drugs Market Size by Type (2023-2028) & (US$ Million)
  • Table 43. Europe Atherosclerosis Drugs Market Size by Application (2017-2022) & (US$ Million)
  • Table 44. Europe Atherosclerosis Drugs Market Size by Application (2023-2028) & (US$ Million)
  • Table 45. Europe Atherosclerosis Drugs Market Size by Country (2017-2022) & (US$ Million)
  • Table 46. Europe Atherosclerosis Drugs Market Size by Country (2023-2028) & (US$ Million)
  • Table 47. Asia Pacific Atherosclerosis Drugs Market Size by Type (2017-2022) & (US$ Million)
  • Table 48. Asia Pacific Atherosclerosis Drugs Market Size by Type (2023-2028) & (US$ Million)
  • Table 49. Asia Pacific Atherosclerosis Drugs Market Size by Application (2017-2022) & (US$ Million)
  • Table 50. Asia Pacific Atherosclerosis Drugs Market Size by Application (2023-2028) & (US$ Million)
  • Table 51. Asia Pacific Atherosclerosis Drugs Market Size by Region (2017-2022) & (US$ Million)
  • Table 52. Asia Pacific Atherosclerosis Drugs Market Size by Region (2023-2028) & (US$ Million)
  • Table 53. Latin America Atherosclerosis Drugs Market Size by Type (2017-2022) & (US$ Million)
  • Table 54. Latin America Atherosclerosis Drugs Market Size by Type (2023-2028) & (US$ Million)
  • Table 55. Latin America Atherosclerosis Drugs Market Size by Application (2017-2022) & (US$ Million)
  • Table 56. Latin America Atherosclerosis Drugs Market Size by Application (2023-2028) & (US$ Million)
  • Table 57. Latin America Atherosclerosis Drugs Market Size by Country (2017-2022) & (US$ Million)
  • Table 58. Latin America Atherosclerosis Drugs Market Size by Country (2023-2028) & (US$ Million)
  • Table 59. Middle East and Africa Atherosclerosis Drugs Market Size by Type (2017-2022) & (US$ Million)
  • Table 60. Middle East and Africa Atherosclerosis Drugs Market Size by Type (2023-2028) & (US$ Million)
  • Table 61. Middle East and Africa Atherosclerosis Drugs Market Size by Application (2017-2022) & (US$ Million)
  • Table 62. Middle East and Africa Atherosclerosis Drugs Market Size by Application (2023-2028) & (US$ Million)
  • Table 63. Middle East and Africa Atherosclerosis Drugs Market Size by Country (2017-2022) & (US$ Million)
  • Table 64. Middle East and Africa Atherosclerosis Drugs Market Size by Country (2023-2028) & (US$ Million)
  • Table 65. GlaxoSmithKline Company Details
  • Table 66. GlaxoSmithKline Business Overview
  • Table 67. GlaxoSmithKline Atherosclerosis Drugs Product
  • Table 68. GlaxoSmithKline Revenue in Atherosclerosis Drugs Business (2017-2022) & (US$ Million)
  • Table 69. GlaxoSmithKline Recent Developments
  • Table 70. Sanofi Company Details
  • Table 71. Sanofi Business Overview
  • Table 72. Sanofi Atherosclerosis Drugs Product
  • Table 73. Sanofi Revenue in Atherosclerosis Drugs Business (2017-2022) & (US$ Million)
  • Table 74. Sanofi Recent Developments
  • Table 75. F. Hoffmann-L a Roche Company Details
  • Table 76. F. Hoffmann-L a Roche Business Overview
  • Table 77. F. Hoffmann-L a Roche Atherosclerosis Drugs Product
  • Table 78. F. Hoffmann-L a Roche Revenue in Atherosclerosis Drugs Business (2017-2022) & (US$ Million)
  • Table 79. F. Hoffmann-L a Roche Recent Developments
  • Table 80. Bayer Company Details
  • Table 81. Bayer Business Overview
  • Table 82. Bayer Atherosclerosis Drugs Product
  • Table 83. Bayer Revenue in Atherosclerosis Drugs Business (2017-2022) & (US$ Million)
  • Table 84. Bayer Recent Developments
  • Table 85. Novartis Company Details
  • Table 86. Novartis Business Overview
  • Table 87. Novartis Atherosclerosis Drugs Product
  • Table 88. Novartis Revenue in Atherosclerosis Drugs Business (2017-2022) & (US$ Million)
  • Table 89. Novartis Recent Developments
  • Table 90. Merck Company Details
  • Table 91. Merck Business Overview
  • Table 92. Merck Atherosclerosis Drugs Product
  • Table 93. Merck Revenue in Atherosclerosis Drugs Business (2017-2022) & (US$ Million)
  • Table 94. Merck Recent Developments
  • Table 95. Janssen Pharmaceutical Company Details
  • Table 96. Janssen Pharmaceutical Business Overview
  • Table 97. Janssen Pharmaceutical Atherosclerosis Drugs Product
  • Table 98. Janssen Pharmaceutical Revenue in Atherosclerosis Drugs Business (2017-2022) & (US$ Million)
  • Table 99. Janssen Pharmaceutical Recent Developments
  • Table 100. Amgen Company Details
  • Table 101. Amgen Business Overview
  • Table 102. Amgen Atherosclerosis Drugs Product
  • Table 103. Amgen Revenue in Atherosclerosis Drugs Business (2017-2022) & (US$ Million)
  • Table 104. Amgen Recent Developments
  • Table 105. Pfizer Company Details
  • Table 106. Pfizer Business Overview
  • Table 107. Pfizer Atherosclerosis Drugs Product
  • Table 108. Pfizer Revenue in Atherosclerosis Drugs Business (2017-2022) & (US$ Million)
  • Table 109. Pfizer Recent Developments
  • Table 110. Research Programs/Design for This Report
  • Table 111. Key Data Information from Secondary Sources
  • Table 112. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Global Atherosclerosis Drugs Market Share by Type: 2021 VS 2028
  • Figure 2. Corticosteroids Features
  • Figure 3. PDE4 Inhibitors Features
  • Figure 4. Biologics Features
  • Figure 5. Skin Barrier Emollients Features
  • Figure 6. CNI Immunosuppressants Features
  • Figure 7. Others Features
  • Figure 8. Global Atherosclerosis Drugs Market Share by Application: 2021 VS 2028
  • Figure 9. Hospital Case Studies
  • Figure 10. Clinic Case Studies
  • Figure 11. Retail Pharmacies Case Studies
  • Figure 12. Other Case Studies
  • Figure 13. Atherosclerosis Drugs Report Years Considered
  • Figure 14. Global Atherosclerosis Drugs Market Size (US$ Million), Year-over-Year: 2017-2028
  • Figure 15. Global Atherosclerosis Drugs Market Size, (US$ Million), 2017 VS 2021 VS 2028
  • Figure 16. Global Atherosclerosis Drugs Market Share by Region: 2021 VS 2028
  • Figure 17. Global Atherosclerosis Drugs Market Share by Players in 2021
  • Figure 18. Global Top Atherosclerosis Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Atherosclerosis Drugs as of 2021)
  • Figure 19. The Top 10 and 5 Players Market Share by Atherosclerosis Drugs Revenue in 2021
  • Figure 20. North America Atherosclerosis Drugs Market Size YoY (2017-2028) & (US$ Million)
  • Figure 21. North America Atherosclerosis Drugs Market Size Market Share by Type (2017-2028)
  • Figure 22. North America Atherosclerosis Drugs Market Size Market Share by Application (2017-2028)
  • Figure 23. North America Atherosclerosis Drugs Market Size Share by Country (2017-2028)
  • Figure 24. United States Atherosclerosis Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 25. Canada Atherosclerosis Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 26. Europe Atherosclerosis Drugs Market Size YoY (2017-2028) & (US$ Million)
  • Figure 27. Europe Atherosclerosis Drugs Market Size Market Share by Type (2017-2028)
  • Figure 28. Europe Atherosclerosis Drugs Market Size Market Share by Application (2017-2028)
  • Figure 29. Europe Atherosclerosis Drugs Market Size Share by Country (2017-2028)
  • Figure 30. Germany Atherosclerosis Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 31. France Atherosclerosis Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 32. U.K. Atherosclerosis Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 33. Italy Atherosclerosis Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 34. Russia Atherosclerosis Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 35. Nordic Countries Atherosclerosis Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 36. Asia-Pacific Atherosclerosis Drugs Market Size YoY (2017-2028) & (US$ Million)
  • Figure 37. Asia Pacific Atherosclerosis Drugs Market Size Market Share by Type (2017-2028)
  • Figure 38. Asia Pacific Atherosclerosis Drugs Market Size Market Share by Application (2017-2028)
  • Figure 39. Asia Pacific Atherosclerosis Drugs Market Size Share by Region (2017-2028)
  • Figure 40. China Atherosclerosis Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 41. Japan Atherosclerosis Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 42. South Korea Atherosclerosis Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 43. Southeast Asia Atherosclerosis Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 44. India Atherosclerosis Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 45. Australia Atherosclerosis Drugs Market Size YoY Growth (2017-2028) & (US$ Million)

List of Figures

  • Figure 46. Latin America Atherosclerosis Drugs Market Size YoY (2017-2028) & (US$ Million)
  • Figure 47. Latin America Atherosclerosis Drugs Market Size Market Share by Type (2017-2028)
  • Figure 48. Latin America Atherosclerosis Drugs Market Size Market Share by Application (2017-2028)
  • Figure 49. Latin America Atherosclerosis Drugs Market Size Share by Country (2017-2028)
  • Figure 50. Mexico Atherosclerosis Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 51. Brazil Atherosclerosis Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 52. Middle East & Africa Atherosclerosis Drugs Market Size YoY (2017-2028) & (US$ Million)
  • Figure 53. Middle East and Africa Atherosclerosis Drugs Market Size Market Share by Type (2017-2028)
  • Figure 54. Middle East and Africa Atherosclerosis Drugs Market Size Market Share by Application (2017-2028)
  • Figure 55. Middle East and Africa Atherosclerosis Drugs Market Size Share by Country (2017-2028)
  • Figure 56. Turkey Atherosclerosis Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 57. Saudi Arabia Atherosclerosis Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 58. UAE Atherosclerosis Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 59. GlaxoSmithKline Revenue Growth Rate in Atherosclerosis Drugs Business (2017-2022)
  • Figure 60. Sanofi Revenue Growth Rate in Atherosclerosis Drugs Business (2017-2022)
  • Figure 61. F. Hoffmann-L a Roche Revenue Growth Rate in Atherosclerosis Drugs Business (2017-2022)
  • Figure 62. Bayer Revenue Growth Rate in Atherosclerosis Drugs Business (2017-2022)
  • Figure 63. Novartis Revenue Growth Rate in Atherosclerosis Drugs Business (2017-2022)
  • Figure 64. Merck Revenue Growth Rate in Atherosclerosis Drugs Business (2017-2022)
  • Figure 65. Janssen Pharmaceutical Revenue Growth Rate in Atherosclerosis Drugs Business (2017-2022)
  • Figure 66. Amgen Revenue Growth Rate in Atherosclerosis Drugs Business (2017-2022)
  • Figure 67. Pfizer Revenue Growth Rate in Atherosclerosis Drugs Business (2017-2022)
  • Figure 68. Bottom-up and Top-down Approaches for This Report
  • Figure 69. Data Triangulation
  • Figure 70. Key Executives Interviewed
目次

This research report focuses on the Atherosclerosis Drugs Market. It analyzes market size, trends and demand forecasts, as well as growth factors and challenges. The report provides market data breakdowns by type, application, company, and region, in addition to competitive landscape and key company profiles.

TABLE OF CONTENTS

1 Report Business Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global Atherosclerosis Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
    • 1.2.2 Corticosteroids
    • 1.2.3 PDE4 Inhibitors
    • 1.2.4 Biologics
    • 1.2.5 Skin Barrier Emollients
    • 1.2.6 CNI Immunosuppressants
    • 1.2.7 Others
  • 1.3 Market by Application
    • 1.3.1 Global Atherosclerosis Drugs Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
    • 1.3.2 Hospital
    • 1.3.3 Clinic
    • 1.3.4 Retail Pharmacies
    • 1.3.5 Other
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Global Growth Trends

  • 2.1 Global Atherosclerosis Drugs Market Perspective (2017-2028)
  • 2.2 Atherosclerosis Drugs Growth Trends by Region
    • 2.2.1 Atherosclerosis Drugs Market Size by Region: 2017 VS 2021 VS 2028
    • 2.2.2 Atherosclerosis Drugs Historic Market Size by Region (2017-2022)
    • 2.2.3 Atherosclerosis Drugs Forecasted Market Size by Region (2023-2028)
  • 2.3 Atherosclerosis Drugs Market Dynamics
    • 2.3.1 Atherosclerosis Drugs Industry Trends
    • 2.3.2 Atherosclerosis Drugs Market Drivers
    • 2.3.3 Atherosclerosis Drugs Market Challenges
    • 2.3.4 Atherosclerosis Drugs Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Atherosclerosis Drugs Players by Revenue
    • 3.1.1 Global Top Atherosclerosis Drugs Players by Revenue (2017-2022)
    • 3.1.2 Global Atherosclerosis Drugs Revenue Market Share by Players (2017-2022)
  • 3.2 Global Atherosclerosis Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
  • 3.3 Players Covered: Ranking by Atherosclerosis Drugs Revenue
  • 3.4 Global Atherosclerosis Drugs Market Concentration Ratio
    • 3.4.1 Global Atherosclerosis Drugs Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Atherosclerosis Drugs Revenue in 2021
  • 3.5 Atherosclerosis Drugs Key Players Head office and Area Served
  • 3.6 Key Players Atherosclerosis Drugs Product Solution and Service
  • 3.7 Date of Enter into Atherosclerosis Drugs Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Atherosclerosis Drugs Breakdown Data by Type

  • 4.1 Global Atherosclerosis Drugs Historic Market Size by Type (2017-2022)
  • 4.2 Global Atherosclerosis Drugs Forecasted Market Size by Type (2023-2028)

5 Atherosclerosis Drugs Breakdown Data by Application

  • 5.1 Global Atherosclerosis Drugs Historic Market Size by Application (2017-2022)
  • 5.2 Global Atherosclerosis Drugs Forecasted Market Size by Application (2023-2028)

6 North America

  • 6.1 North America Atherosclerosis Drugs Market Size (2017-2028)
  • 6.2 North America Atherosclerosis Drugs Market Size by Type
    • 6.2.1 North America Atherosclerosis Drugs Market Size by Type (2017-2022)
    • 6.2.2 North America Atherosclerosis Drugs Market Size by Type (2023-2028)
    • 6.2.3 North America Atherosclerosis Drugs Market Share by Type (2017-2028)
  • 6.3 North America Atherosclerosis Drugs Market Size by Application
    • 6.3.1 North America Atherosclerosis Drugs Market Size by Application (2017-2022)
    • 6.3.2 North America Atherosclerosis Drugs Market Size by Application (2023-2028)
    • 6.3.3 North America Atherosclerosis Drugs Market Share by Application (2017-2028)
  • 6.4 North America Atherosclerosis Drugs Market Size by Country
    • 6.4.1 North America Atherosclerosis Drugs Market Size by Country (2017-2022)
    • 6.4.2 North America Atherosclerosis Drugs Market Size by Country (2023-2028)
    • 6.4.3 U.S.
    • 6.4.4 Canada

7 Europe

  • 7.1 Europe Atherosclerosis Drugs Market Size (2017-2028)
  • 7.2 Europe Atherosclerosis Drugs Market Size by Type
    • 7.2.1 Europe Atherosclerosis Drugs Market Size by Type (2017-2022)
    • 7.2.2 Europe Atherosclerosis Drugs Market Size by Type (2023-2028)
    • 7.2.3 Europe Atherosclerosis Drugs Market Share by Type (2017-2028)
  • 7.3 Europe Atherosclerosis Drugs Market Size by Application
    • 7.3.1 Europe Atherosclerosis Drugs Market Size by Application (2017-2022)
    • 7.3.2 Europe Atherosclerosis Drugs Market Size by Application (2023-2028)
    • 7.3.3 Europe Atherosclerosis Drugs Market Share by Application (2017-2028)
  • 7.4 Europe Atherosclerosis Drugs Market Size by Country
    • 7.4.1 Europe Atherosclerosis Drugs Market Size by Country (2017-2022)
    • 7.4.2 Europe Atherosclerosis Drugs Market Size by Country (2023-2028)
    • 7.4.3 Germany
    • 7.4.4 France
    • 7.4.5 U.K.
    • 7.4.6 Italy
    • 7.4.7 Russia
    • 7.4.8 Nordic Countries

8 Asia-Pacific

  • 8.1 Asia-Pacific Atherosclerosis Drugs Market Size (2017-2028)
  • 8.2 Asia-Pacific Atherosclerosis Drugs Market Size by Type
    • 8.2.1 Asia-Pacific Atherosclerosis Drugs Market Size by Type (2017-2022)
    • 8.2.2 Asia-Pacific Atherosclerosis Drugs Market Size by Type (2023-2028)
    • 8.2.3 Asia-Pacific Atherosclerosis Drugs Market Share by Type (2017-2028)
  • 8.3 Asia-Pacific Atherosclerosis Drugs Market Size by Application
    • 8.3.1 Asia-Pacific Atherosclerosis Drugs Market Size by Application (2017-2022)
    • 8.3.2 Asia-Pacific Atherosclerosis Drugs Market Size by Application (2023-2028)
    • 8.3.3 Asia-Pacific Atherosclerosis Drugs Market Share by Application (2017-2028)
  • 8.4 Asia-Pacific Atherosclerosis Drugs Market Size by Region
    • 8.4.1 Asia-Pacific Atherosclerosis Drugs Market Size by Region (2017-2022)
    • 8.4.2 Asia-Pacific Atherosclerosis Drugs Market Size by Region (2023-2028)
    • 8.4.3 China
    • 8.4.4 Japan
    • 8.4.5 South Korea
    • 8.4.6 Southeast Asia
    • 8.4.7 India
    • 8.4.8 Australia

9 Latin America

  • 9.1 Latin America Atherosclerosis Drugs Market Size (2017-2028)
  • 9.2 Latin America Atherosclerosis Drugs Market Size by Type
    • 9.2.1 Latin America Atherosclerosis Drugs Market Size by Type (2017-2022)
    • 9.2.2 Latin America Atherosclerosis Drugs Market Size by Type (2023-2028)
    • 9.2.3 Latin America Atherosclerosis Drugs Market Share by Type (2017-2028)
  • 9.3 Latin America Atherosclerosis Drugs Market Size by Application
    • 9.3.1 Latin America Atherosclerosis Drugs Market Size by Application (2017-2022)
    • 9.3.2 Latin America Atherosclerosis Drugs Market Size by Application (2023-2028)
    • 9.3.3 Latin America Atherosclerosis Drugs Market Share by Application (2017-2028)
  • 9.4 Latin America Atherosclerosis Drugs Market Size by Country
    • 9.4.1 Latin America Atherosclerosis Drugs Market Size by Country (2017-2022)
    • 9.4.2 Latin America Atherosclerosis Drugs Market Size by Country (2023-2028)
    • 9.4.3 Mexico
    • 9.4.4 Brazil

10 Middle East & Africa

  • 10.1 Middle East & Africa Atherosclerosis Drugs Market Size (2017-2028)
  • 10.2 Middle East & Africa Atherosclerosis Drugs Market Size by Type
    • 10.2.1 Middle East & Africa Atherosclerosis Drugs Market Size by Type (2017-2022)
    • 10.2.2 Middle East & Africa Atherosclerosis Drugs Market Size by Type (2023-2028)
    • 10.2.3 Middle East & Africa Atherosclerosis Drugs Market Share by Type (2017-2028)
  • 10.3 Middle East & Africa Atherosclerosis Drugs Market Size by Application
    • 10.3.1 Middle East & Africa Atherosclerosis Drugs Market Size by Application (2017-2022)
    • 10.3.2 Middle East & Africa Atherosclerosis Drugs Market Size by Application (2023-2028)
    • 10.3.3 Middle East & Africa Atherosclerosis Drugs Market Share by Application (2017-2028)
  • 10.4 Middle East & Africa Atherosclerosis Drugs Market Size by Country
    • 10.4.1 Middle East & Africa Atherosclerosis Drugs Market Size by Country (2017-2022)
    • 10.4.2 Middle East & Africa Atherosclerosis Drugs Market Size by Country (2023-2028)
    • 10.4.3 Turkey
    • 10.4.4 Saudi Arabia
    • 10.4.5 UAE

11 Key Players Profiles

  • 11.1 GlaxoSmithKline
    • 11.1.1 GlaxoSmithKline Company Details
    • 11.1.2 GlaxoSmithKline Business Overview
    • 11.1.3 GlaxoSmithKline Atherosclerosis Drugs Introduction
    • 11.1.4 GlaxoSmithKline Revenue in Atherosclerosis Drugs Business (2017-2022)
    • 11.1.5 GlaxoSmithKline Recent Developments
  • 11.2 Sanofi
    • 11.2.1 Sanofi Company Details
    • 11.2.2 Sanofi Business Overview
    • 11.2.3 Sanofi Atherosclerosis Drugs Introduction
    • 11.2.4 Sanofi Revenue in Atherosclerosis Drugs Business (2017-2022)
    • 11.2.5 Sanofi Recent Developments
  • 11.3 F. Hoffmann-L a Roche
    • 11.3.1 F. Hoffmann-L a Roche Company Details
    • 11.3.2 F. Hoffmann-L a Roche Business Overview
    • 11.3.3 F. Hoffmann-L a Roche Atherosclerosis Drugs Introduction
    • 11.3.4 F. Hoffmann-L a Roche Revenue in Atherosclerosis Drugs Business (2017-2022)
    • 11.3.5 F. Hoffmann-L a Roche Recent Developments
  • 11.4 Bayer
    • 11.4.1 Bayer Company Details
    • 11.4.2 Bayer Business Overview
    • 11.4.3 Bayer Atherosclerosis Drugs Introduction
    • 11.4.4 Bayer Revenue in Atherosclerosis Drugs Business (2017-2022)
    • 11.4.5 Bayer Recent Developments
  • 11.5 Novartis
    • 11.5.1 Novartis Company Details
    • 11.5.2 Novartis Business Overview
    • 11.5.3 Novartis Atherosclerosis Drugs Introduction
    • 11.5.4 Novartis Revenue in Atherosclerosis Drugs Business (2017-2022)
    • 11.5.5 Novartis Recent Developments
  • 11.6 Merck
    • 11.6.1 Merck Company Details
    • 11.6.2 Merck Business Overview
    • 11.6.3 Merck Atherosclerosis Drugs Introduction
    • 11.6.4 Merck Revenue in Atherosclerosis Drugs Business (2017-2022)
    • 11.6.5 Merck Recent Developments
  • 11.7 Janssen Pharmaceutical
    • 11.7.1 Janssen Pharmaceutical Company Details
    • 11.7.2 Janssen Pharmaceutical Business Overview
    • 11.7.3 Janssen Pharmaceutical Atherosclerosis Drugs Introduction
    • 11.7.4 Janssen Pharmaceutical Revenue in Atherosclerosis Drugs Business (2017-2022)
    • 11.7.5 Janssen Pharmaceutical Recent Developments
  • 11.8 Amgen
    • 11.8.1 Amgen Company Details
    • 11.8.2 Amgen Business Overview
    • 11.8.3 Amgen Atherosclerosis Drugs Introduction
    • 11.8.4 Amgen Revenue in Atherosclerosis Drugs Business (2017-2022)
    • 11.8.5 Amgen Recent Developments
  • 11.9 Pfizer
    • 11.9.1 Pfizer Company Details
    • 11.9.2 Pfizer Business Overview
    • 11.9.3 Pfizer Atherosclerosis Drugs Introduction
    • 11.9.4 Pfizer Revenue in Atherosclerosis Drugs Business (2017-2022)
    • 11.9.5 Pfizer Recent Developments

12 Analyst's Viewpoints/Conclusions

13 Appendix

  • 13.1 Research Methodology
    • 13.1.1 Methodology/Research Approach
    • 13.1.2 Data Source
  • 13.2 Author Details
  • 13.3 Disclaimer